Hypophosphatasia features selective deficiency of activity of the tissue-nonspecific (liver/bone/kidney) alkaline phosphatase (ALP) To test whether human PALP and TNSALP are physiologically active toward the same substrates, we studied PEA, PPi, and PLP levels during and after pregnancy in three women who are carriers for hypophosphatasia. Hypophosphatasemia corrected during the third trimester because of PALP in maternal blood. Blood or urine concentrations of PEA, PPi, and PLP diminished substantially during that time. After childbirth, maternal circulating levels of PALP decreased, and PEA, PPi, and PLP levels abruptly increased. In serum, unremarkable concentrations of IALP and low levels of TNSALP did not change during the study period.
Nevertheless, the physiological role(s) of these enzymes is poorly understood (2) . Their biochemical designation (orthophosphoric monoester phosphohydrolase [alkaline optimum]: EC 3.1.3.1) reflects catalytic properties characterized in vitro (1) .
In humans, at least four genes encode ALP isoenzymes (3). Three ALP genes at chromosome 2q34-37 are expressed in essentially a tissue-specific manner and produce a placental, placental-like, and intestinal ALP isoenzyme (PALP, PLALP, and IALP, respectively). The fourth ALP gene, at chromosome lp36.1-34, encodes a family of proteins that differ from one another only by posttranslational modification; these secondary ALP isoenzymes are present throughout the body, but individually are most abundant in hepatic, skeletal, and renal tissue (4) . Accordingly, they are collectively called liver/bone/kidney or tissue-nonspecific ALP (TNSALP) (1-4). At the amino acid level, the tissue-specific ALP isoenzymes are 86-98% identical to one another (5, 6 ), but 52-56% identical when compared with TNSALP (7) .
Insight concerning the physiological function of TNSALP in humans has come from investigation of hypophosphatasia (2, 8) , a rare heritable metabolic bone disease characterized biochemically by a deficiency of TNSALP activity (9) . Clinical features include rickets in children or osteomalacia in adults and premature loss of teeth because of defective formation of dental cementum (9) . In hypophosphatasia, three phosphocompounds (phosphoethanolamine [PEA] , inorganic pyrophosphate [PPi] , and pyridoxal 5'-phosphate [PLP]) accumulate endogenously and appear, therefore, to be natural substrates for TNSALP (8, 9) . PPi is an inhibitor of calcification and, accordingly, increased levels could account for the skeletal disease (8, 10) . Identification of 12 missense mutations to date within the TNSALP gene (11) (12) (13) and Henthom, P. S., M. Raducha, V. Fimiani, K. N. Fedde, and M. P. Whyte, manuscript in preparation) associated with hypophosphatasia and a transfection study, which showed that-one of these nucleotide changes destroyed the enzyme's catalytic action ( 11) (8) .
Although investigation of hypophosphatasia has provided considerable insight concerning the biological role of TNSALP (8) in biomineralization, inborn errors of PALP, PLALP, and IALP biosynthesis have not been described, and the function of these tissue-specific ALP isoenzymes is less well understood (1) . ALP gene knockout models in animals have not yet been reported. Furthermore, the tissue specificity and organization of the human ALP genes is not homologous in mice (1) , and murine knockout models will not be completely analogous for exploring human ALP isoenzyme function.
X-ray crystallographic study of Escherichia coli ALP (14) together with comparisons of the ALP proteins of a variety of organisms (15, 16) indicate that the core structure, active site, and catalytic mechanism of this enzyme have been significantly conserved throughout evolution. Accordingly, we hypothesized that PALP and TNSALP (and by extrapolation all four of the ALP isoenzymes in humans) possess similar substrate specificity. We tested this hypothesis by studying throughout and after pregnancy women who were hypophosphatasia carriers (i.e., TNSALP-deficient). In the course of the investigation, we quantitated serum ALP isoenzymes, plasma PLP, and urinary PEA and PPi. We predicted that levels of these three phosphocompounds would diminish during the latter stages of gestation when significant amounts of PALP are synthesized endogenously if, in fact, the substrate specificity of PALP is similar to TNSALP.
Methods
Subjects. Subjects A, B, and C each had had a child with either the moderately severe childhood form or more mild odonto form of hypophosphatasia (9) . Each woman had participated in a screening investigation of their kindred (before the pregnancy study described (17) (18) (19) (20) 
Results
The biochemical findings during each of the three pregnancies were similar and are illustrated in Fig. 1 . ALP isoenzymes during pregnancy. As described previously, each woman had been shown to be hypophosphatasemic before her pregnancy. Subjects A and B showed gradual increases in serum total ALP activity (Fig. 1 , row I of panels) beginning at about 5 mo of gestation. Relatively rapid increments occurred during the third trimester until the time of fullterm delivery (designated by arrows). Compared with the normal range for serum total ALP activity in normal adults in St.
Louis, these increases corrected subnormal (nonpregnant) levels by the sixth month of gestation. At -8 mo of gestation, the serum total ALP activity levels were elevated. Subject C, who was studied only at delivery and after childbirth, had values for serum total ALP activity that had risen into the normal adult range at the time of parturition.
The increases in serum total ALP in subjects A and B were due exclusively to PALP (Fig. 2) . Subject A, at 4 mo of pregnancy, had PALP comprise 22% of her serum total ALP. However, during the month before delivery, > 90% of her serum total ALP was PALP. In fact, at the time of parturition, total ALP activity was 92% PALP, 7% TNSALP, and 1% IALP. Quantitation of TNSALP showed subnormal and unchanged values during and after the pregnancy; IALP was always a very small percentage of the total. Subject B manifested 16% of her serum total ALP as PALP at 4.5 mo of pregnancy. 1 mo before delivery her serum total ALP activity was 113 IU/liter (normal (24) , have an exaggerated plasma PLP level response when given an oral pyridoxine challenge.
quently, there were sizable decreases in plasma or urine levels of PLP, PEA, and PPi ( Fig. 1) even before PALP had normalized serum total ALP activity in her circulation. During the third trimester of pregnancy, plasma PLP concentrations (Fig.  1, row II) had nearly corrected despite vitamin supplementation, urinary PEA levels (Fig. 1, row III) were normal, and urinary PPi levels (Fig. 1, row IV) became undetectable. Very similar changes occurred for subject B who normalized her plasma PLP concentrations and urine PEA levels and had urinary PPi levels below the limits of detection during the third trimester of pregnancy.
Postpartum findings. After parturition, serum total ALP activity (-PALP) decreased with a measured half-life for subjects A, B, and C of 1.8, 2.1, and 4.5 d, respectively (Fig. 1) . Urinary PEA and PPi levels, however, were found to rise abruptly. Elevated centrations were noted in subject A at a time when her serum total ALP was still in the normal range. Especially high plasma PLP concentrations were demonstrated for subjects A and C several months after childbirth when they were once again clearly hypophosphatasemic and prenatal vitamins were continued.
Offspring. Subject A delivered a boy whose cord serum revealed hypophosphatasemia (total ALP activity 15 IU/liter) and an elevated plasma PLP concentration of 1,989 nM (previously, we had assayed cord blood from two newborn controls [mothers presumably receiving vitamins] whose serum total ALP activities were 109 and 135 IU/liter, and plasma PLP concentrations were 180 and 275 nM [25] ). Now, 7 yr old, like his affected older brother, he has had premature loss of deciduous teeth and has subtle rachitic changes on skeletal radiographs. Therefore, he mildly manifests the childhood form of hypophosphatasia. Molecular analysis revealed that he (like his mother, brother, sister, and several other maternal relatives with biochemical findings consistent with hypophosphatasia) carries the 1 309-T TNSALP missense mutation. Subject (26) . Failure of TNSALP to hydrolyze PPi, an inhibitor of biomineralization, offers a plausible explanation for the associated skeletal disease (8, 10) . Hypophosphatasia, however, raises intriguing questions about the physiological role of TNSALP elsewhere in the body, because organs other than the skeleton that are also TNSALP-rich (e.g., liver, kidney, adrenal glands) do not significantly malfunction (2, 8) . Indeed, after considerable investigative effort, a great variety of physiological roles has been suggested not only for TNSALP, but for all four ALP isoenzymes in humans ( 1 ) (for review see reference 8). The absence of human models for PALP, PLALP, or IALP deficiency has hindered our understanding of the role of the three tissue-specific ALP isoenzymes (1, 4, 27) . Furthermore, separate genes for PALP and PLALP are found only in higher primates (1); thus, development of animal models is problematic.
The decreases in blood and urine levels of PEA, PPi, and PLP that we observed during the pregnancies of three women who are carriers for hypophosphatasia are consistent with our aforementioned speculation, based upon comparable substrate binding site structures throughout nature ( 15, 16) , that all ALP isoenzymes in humans have at least overlapping specificities for physiological substrates. Our findings show that PALP acts in vivo to hydrolyze the same substrates as TNSALP, i.e., PEA, PPi, and PLP which are sensitive biochemical markers for hypophosphatasia (28) . In our study subjects, elevated plasma PLP concentrations and increased urinary PEA levels normalized and urinary PPi became undetectable during the third trimester of pregnancy when PALP was present endogenously as shown by significant PALP levels in serum. Reviewed below, these biochemical observations seem attributable to PALP (rather than some other phosphatase), and specifically to PALP in the placenta itself, not PALP in the circulation.
In human tissues, all forms of ALP are primarily bound to the external surface of cells (29, 30) . ALP isoenzyme patterns in the circulation are believed to reflect their source in specific organs ( I). For healthy adults, approximately equal amounts of the bone and liver forms of the TNSALP isoenzyme comprise most of the ALP in serum (23, 31) ; IALP makes up only a small percentage of the total (1, 23 (6, 27) , but are normally difficult to detect except for PALP during pregnancy (23) .
PALP is expressed from the genome of the fetus. Early during the first trimester of pregnancy, PALP in the chorionic villus is essentially absent (32) . PALP then appears predominantly on the plasma membrane of the maternal surface of syncytiotrophoblast microvilli (33, 34) . Changes in maternal serum ALP isoenzyme levels during gestation have been thoroughly studied (35) (36) (37) . For uneventful pregnancies, serum total ALP activity rises gradually between the first and second trimesters, then rapidly increases further during the third trimester. The increments are due both to PALP and to some increase in the bone form of TNSALP (38) . In their comprehensive review Alkaline Phosphatase, McComb, Bowers, and Posen (1) cite the experimental evidence that "established beyond doubt that the enhanced level of serum ALP in pregnant women is due predominantly to the enrichment of the circulation with enzyme of placental origin" (35) (36) (37) (38) . Although approximately a doubling of the bone form of TNSALP in serum occurs between the second and third trimesters of pregnancy, which persists for 6 wk after delivery (38, 39) , the changes in PALP are greater. During the third trimester, normally 40-67% of the total ALP in maternal serum is PALP (36) . 3 Since expression of PALP is controlled by the fetal genome, one would not expect a defect in PALP biosynthesis in hypophosphatasia (33) . Women who are affected by, or are carriers for, hypophosphatasia would, therefore, be excellent models for exploring the physiological effect of PALP. PALP appearance endogenously would occur on a background of TNSALP deficiency and with little (if any) change in other ALPs. In fact, we observed unremarkable temporal and quantitative aspects of PALP biosynthesis during the closely followed pregnancies of our study subjects. An especially high percentage of their serum total ALP at delivery was PALP, i.e., 92, 81, and 73% in subjects A, B, and C, respectively. We found no change in their deficient TNSALP or unremarkable IALP levels in serum.
Our ability to assess the impact of endogenous biosynthesis of PALP per se seemed especially good in subject A. Her newborn was affected by hypophosphatasia as shown by his cord blood that had low serum ALP activity and elevated plasma PLP concentrations and his subsequent clinical course. Changes observed in her endogenous PEA, PPi, and PLP levels were, therefore, unlikely to have been influenced by fetal TNSALP. In fact, as exemplified by PLP (41) , phosphorylated compounds do not readily cross the fetal/maternal placental barrier, and PALP does not have access to the fetal circulation (42) .
The placenta has complex endocrine functions and synthesizes placental-specific enzymes (43, 44) . Conceivably, biosynthesis of some phosphatase other than PALP by the placenta could have accounted for the observed changes in PEA, PPi, and PLP. However, the temporal relationship between the changes in serum PALP levels and the decreases in PEA, PPi, and PLP levels was consistent with hydrolysis of these phosphocompounds by PALP.
Evidence that PALP within the placenta itself, rather than in the circulation, caused the observed changes in PEA, PPi, and 3. During pregnancy there is typically some increase in neutrophil ALP activity, which has been shown to be a form of TNSALP (40) , but this ALP constitutes only a small amount of the total ALP activity in the circulation, and can be subnormal in all clinical forms of hypophosphatasia (9).
PLP comes from examination of the timing of the biochemical changes. The half-life for PALP infused into volunteers has been reported to be 7 d (45) . In normal pregnant women, a monoclonal antibody-based, solid-phase, enzyme-binding assay for serum PALP showed an immediate postpartum drop within 4 d to values approaching nonpregnant levels (37) . Postpartum, the serum PALP of our study subjects decreased with calculated half-lives of 1.8-4.5 d. We observed, however, that urinary PEA and PPi levels, and perhaps plasma PLP concentrations as well, increased more abruptly than circulating PALP dissipated at the time of delivery. Although the rapidity of the changes was somewhat difficult to illustrate in Fig. 1 , assay of spot urine collections demonstrated a very rapid increase in urinary PEA and PPi levels within the first day postpartum. The relatively gradual decrease of PALP levels in the circulation over several days did not reflect these changes. Indeed, at a time when serum total ALP was still in the normal range, urinary levels of PEA and PPi had clearly increased. Sudden physiological expulsion of the placenta and its PALP during parturition seemed to explain the rapid reaccumulation of these ALP substrates. Similarly, early in the pregnancies, when relatively small amounts of PALP were detectable in serum, there already had been a significant decrement in plasma PLP concentrations into the normal range, partial correction of urinary PEA levels, and almost virtual disappearance of PPi from the urine. These cumulative observations are consistent with reports that ALP in situ, rather than in the circulation, is physiologically active (2, 8, 9, (45) (46) (47) (48) (49) .
Of interest, our previous studies of a large kindred with the adult form of hypophosphatasia suggested that phosphoserine (PS) could be a physiological substrate for TNSALP. In hypophosphatasemic subjects, there was a negative correlation between urinary PS levels and serum levels of the liver form of TNSALP (17, 31) . However, urinary concentrations of PS in subjects A, B, and C were not increased and remained essentially unchanged during the study period (data not shown). Thus, we found no evidence in this investigation of hypophosphasia carriers that PS is a physiological substrate for TNSALP or PALP.
Our investigation of hypophosphatasia carriers indicates that PEA, PPi, and PLP are physiological substrates not only for TNSALP but for PALP as well. Possibly, all ALPs in nature can hydrolyze these phosphocompounds. Although in humans TNSALP acts critically in biomineralization, this promiscuous substrate specificity may reflect a role for ALPs both in the liberation of nonphosphate moieties as well as Pi. All ALP products of hydrolysis could then enter cells-a hypothesis that was proposed after study of yeast in the early part of this century (1) .
